Coya Therapeutics' ALS Drug Earns Fast Track, $11.1M Private Placement Bolsters Balance Sheet
summarizeSummary
Coya Therapeutics announced a highly positive Q1 2026 update, highlighted by the FDA granting Fast Track Designation to COYA 302 for ALS, a significant regulatory milestone that expedites development and review. Concurrently, the company secured an $11.1 million private placement, substantially strengthening its balance sheet and extending its cash runway. This capital raise, led by Dr. Reddy's Laboratories and Greenlight Capital, is material for a company of Coya's size. The company also reported FDA acceptance of an IND for COYA 302 in frontotemporal dementia (FTD) and positive results from an investigator-initiated FTD study. Furthermore, Coya amended its ALSTARS trial protocol to broaden patient eligibility, which is expected to accelerate enrollment. With $50.7 million in cash and cash equivalents as of March 31, 2026, and a net loss of $7.2 million, Coya is well-capitalized to advance its clinical pipeline. Traders will be watching for the upcoming catalysts in the second half of 2026, including full enrollment of the ALSTARS trial and initiation of the Phase 2a FTD study.
At the time of this announcement, COYA was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.1M. The 52-week trading range was $3.71 to $7.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.